REG - N4 Pharma PLC - Partnership with University of Strathclyde’s CMAC

N4 PharmaAnnouncement

23/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250923:nRSW2764Aa&default-theme=true

RNS Number : 2764A  N4 Pharma PLC  23 September 2025

 

23 September 2025

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

Partnership with University of Strathclyde's CMAC National Facility

Collaboration combines N4 Pharma's innovative Nuvec® delivery platform with
CMAC's world-class expertise to accelerate development and broaden therapeutic
applications

 

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary
gene delivery system to enable advanced therapies for cancer and other
diseases, is pleased to announce a collaboration with CMAC, based at the
University of Strathclyde in Glasgow.

 

CMAC is a leading international manufacturing research centre with a unique
configuration of academic research, applied projects and pre-competitive
programmes. Working with industry partners, academic institutions and
innovation collaborators, CMAC's mission is to transform medicine development,
manufacture and supply.

 

This collaboration brings together the expertise of Professor Yvonne Perrie,
MBE, Head of the Strathclyde Institute of Pharmacy and Biomedical Sciences,
alongside CMAC's National Facility team and N4 Pharma's scientific experts.
The collaboration will focus on advancing the Nuvec® platform towards
clinical readiness and characterising additional dual-loaded Nuvec®
preclinical candidates, both in vitro and in vivo.

 

Professor Perrie is an internationally recognised authority in drug delivery,
RNA vaccines and nanomedicine manufacturing, combining academic leadership,
regulatory expertise and extensive industry collaboration. She began her
career with Lipoxen Technologies Ltd, developing liposomal drug delivery
platforms before moving into academia, where she has built a leading research
portfolio in advanced drug and vaccine delivery. She has published more than
150 papers, is an inventor on multiple patents and serves on the Scientific
Advisory Board of Quotient Sciences. Professor Perrie is also a Commissioner
on the UK's Commission on Human Medicines and has advised the MHRA, WHO and
other international regulators. In 2024, she was awarded an MBE for services
to pharmaceutical innovation and regulation.

 

Her work with industry partners is extensive. With AstraZeneca, she has led
projects on lipid nanoparticle characterisation and advanced analytics. With
GSK Vaccines Siena, she directed studies on cationic lipid nanoparticles for
self-amplifying RNA vaccines and on how nanoparticle design influences vaccine
potency. With Pfizer, she has collaborated through the CPI consortium on
microfluidics and the Medicines Manufacturing Innovation Centre, advancing
innovation in nanomedicine manufacturing.

 

Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:

 

"We are delighted to partner with the University of Strathclyde and CMAC's
National Facility. This collaboration builds upon excellent progress in our
own programmes over the past few months and represents an important step in
strengthening the commercial data package for Nuvec®, giving us access to
world-class expertise and facilities to accelerate its development.

 

"Working with Professor Perrie and the CMAC world-class scientists enhances
our ability to characterise Nuvec® in depth, showcase its unique benefits and
explore its broader therapeutic applications. These efforts bring us closer to
our goal of positioning Nuvec® as a leading gene delivery platform for
nucleic acid therapies, supporting both our internal pipeline and future
licensing opportunities."

 
Professor Yvonne Perrie, MBE, added:

 

"We are excited to collaborate with N4 Pharma on the continued development of
the Nuvec® platform. Our work at CMAC's National Facility is focused on
advancing innovation in drug delivery and pharmaceutical manufacturing.
Partnering with N4 Pharma provides an excellent opportunity to apply our
expertise in RNA vaccines and nanomedicine manufacturing to help accelerate
the Nuvec® programme towards clinical readiness and broaden its potential
applications."

Massimo Bresciani, Industry Director of CMAC, commented:

"This project demonstrates the strength of industry-academic partnerships in
accelerating medicines manufacturing. By combining N4 Pharma's innovative
delivery platform with CMAC's technical expertise, we aim to unlock new
possibilities in RNA therapeutics."

- Ends -

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                                       Via N4 Pharma Investor Hub: investors.n4pharma.com

                                                                         (https://investors.n4pharma.com/)
 Luke Cairns, Executive Director

                                                                         https://n4pharma.com/link/yEMX3y (https://n4pharma.com/link/yEMX3y)
 Submit your questions directly to the management team via the N4 Pharma

 Investor Hub
 SP Angel Corporate Finance LLP                                            Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Jen Clarke (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                                     Tel: +44 (0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope
 Northstar Communications Limited                                          Tel: +44 (0)113 730 3896

 Investor Relations

 Sarah Hollins

 

About N4 Pharma

 

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its
proprietary gene delivery system, to enable advanced therapies for cancer and
other diseases.

 

RNA therapeutics are set to impact the treatment of a wide range of diseases
and Nuvec® has several key advantages for RNA gene delivery including the
ability to deliver multiple RNA therapies in a single particle, ease of
manufacturing, protection of the RNA payload to allow for oral delivery, no
unwanted immune response and excellent stability and storage.

 

N4 Pharma is building out its preclinical data set and working towards
first-in-human clinical data to support significant licensing deals for its
Nuvec® platform with gene therapy partners.

 

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for
IBD which serves as a proof-of-concept programme showcasing all the benefits
of the Nuvec® platform.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at
https://investors.n4pharma.com/auth/signup
(https://investors.n4pharma.com/auth/signup) .

 

About CMAC

 

CMAC is an internationally leading medicines manufacturing research centre
with a unique configuration of academic research, applied and pre-competitive
programmes.

 

Working in partnership with large pharma, technology providers, academic and
innovation partners, CMAC's goal is to transform medicines development,
manufacture and supply and further grow its pipeline of world-class
multi-disciplinary collaborative research.

 

The centre's portfolio currently includes the Made Smarter Innovation: Digital
Medicines Manufacturing Research Centre (DM²), EPSRC international Digital
Design and Manufacture of Amorphous Pharmaceuticals (DDMAP) collaboration,
UKRPIF supported Net Zero Pilot and CMAC Data Lab, EPSRC CDT Cyber-physical
Systems for Medicines Manufacturing (CEDAR), and the EPSRC MediForge Hub,
along with training and translation projects within a world-class facility.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPKBBDDBKDBCB